+

WO2005076012A3 - Novel splice variants and methods of use thereof - Google Patents

Novel splice variants and methods of use thereof Download PDF

Info

Publication number
WO2005076012A3
WO2005076012A3 PCT/US2005/002695 US2005002695W WO2005076012A3 WO 2005076012 A3 WO2005076012 A3 WO 2005076012A3 US 2005002695 W US2005002695 W US 2005002695W WO 2005076012 A3 WO2005076012 A3 WO 2005076012A3
Authority
WO
WIPO (PCT)
Prior art keywords
splice variants
methods
novel splice
polypeptides
useful
Prior art date
Application number
PCT/US2005/002695
Other languages
French (fr)
Other versions
WO2005076012A2 (en
Inventor
Keting Chu
Amy L Tsui Collins
Ernestine Lee
Justin G P Wong
Original Assignee
Five Prime Therapeutics Inc
Keting Chu
Amy L Tsui Collins
Ernestine Lee
Justin G P Wong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Keting Chu, Amy L Tsui Collins, Ernestine Lee, Justin G P Wong filed Critical Five Prime Therapeutics Inc
Publication of WO2005076012A2 publication Critical patent/WO2005076012A2/en
Publication of WO2005076012A3 publication Critical patent/WO2005076012A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to splice variants of polypeptides that are highly expressed in tumor tissues. Such polypeptides are useful for therapeutic, diagnostic, and prophylactic purposes. In particular, the polypeptides herein are useful as targets for development of modulators for treatment of diseases.
PCT/US2005/002695 2004-01-30 2005-01-31 Novel splice variants and methods of use thereof WO2005076012A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54074504P 2004-01-30 2004-01-30
US60/540,745 2004-01-30

Publications (2)

Publication Number Publication Date
WO2005076012A2 WO2005076012A2 (en) 2005-08-18
WO2005076012A3 true WO2005076012A3 (en) 2006-02-16

Family

ID=34837419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/002695 WO2005076012A2 (en) 2004-01-30 2005-01-31 Novel splice variants and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2005076012A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0519376D0 (en) * 2005-09-23 2005-11-02 Astrazeneca Ab Diagnostic method
CN116284224B (en) * 2023-05-12 2023-07-25 中国农业大学 Cyclic peptide combined with Claudin18.2 and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033979A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Bone marrow secreted proteins and polynucleotides
US5968744A (en) * 1997-10-14 1999-10-19 Incyte Pharmaceticals, Inc. Human cornichon molecule
WO2001077289A2 (en) * 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
WO2003042357A2 (en) * 2001-09-28 2003-05-22 Incyte Genomics, Inc. Enzymes
EP1347046A1 (en) * 2002-03-22 2003-09-24 Research Association for Biotechnology Full-length cDNA sequences
US20030211096A1 (en) * 1999-08-31 2003-11-13 Genentech, Inc. Compositions and methods for the treatment of tumor
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968744A (en) * 1997-10-14 1999-10-19 Incyte Pharmaceticals, Inc. Human cornichon molecule
WO1999033979A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Bone marrow secreted proteins and polynucleotides
US20030211096A1 (en) * 1999-08-31 2003-11-13 Genentech, Inc. Compositions and methods for the treatment of tumor
WO2001077289A2 (en) * 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
WO2003042357A2 (en) * 2001-09-28 2003-05-22 Incyte Genomics, Inc. Enzymes
EP1347046A1 (en) * 2002-03-22 2003-09-24 Research Association for Biotechnology Full-length cDNA sequences
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 29 August 2003 (2003-08-29), XP002346302, retrieved from EBI Database accession no. CF374855 *
DATABASE EMBL [online] 6 September 2001 (2001-09-06), XP002346301, retrieved from EBI Database accession no. BI559784 *

Also Published As

Publication number Publication date
WO2005076012A2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2006081826A3 (en) Survivin peptide vaccine
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
EP2759302A3 (en) 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2006099610A3 (en) Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
WO2007044026A3 (en) Compositions comprising modified collagen and uses therefore
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2006050058A3 (en) Methods of detection and therapy of inflamed tissues using immune modulation
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
WO2004112829A3 (en) Compositions and methods for the diagnosis and treatment of tumors of glial origin
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2007111661A3 (en) Human antibodies specific for gastrin materials and methods
EP2175879A4 (en) Treatment of prion protein related diseases
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EA201070195A1 (en) DERIVATIVES 1,2,3,4-TETRAGIDROPYRROLO [1,2-A] PIRAZIN-6-CARBOXAMIDES AND 2,3,4,5-TETRAHYDROPYRROLO [1,2-a] [1,4] -DIAZEPIN-7-CARBOXAMIDES , THEIR RECEIVING AND THEIR APPLICATION IN THERAPY
WO2006029176A3 (en) Cancer-testis antigens
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载